Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat

Cellular Physiology and Biochemistry

Volumn 29, Issue 5-6, 2012, Pages 833-840

  Lammers, Carina ^a   Dartsch, Theresa ^a   Brandt, Mathias C ^a   Rottländer, Dennis ^a   Halbach, Marcel ^a   Peinkofer, Gabriel ^a   Ockenpoehler, Simon ^a   Weiergraeber, Marco ^b   Schneider, Toni ^a   Reuter, Hannes ^a   Müller Ehmsen, Jochen ^a   Hescheler, Jürgen ^a   Hoppe, Uta C ^a   Zobel, Carsten ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Bundesinstitut fur Arzneimittel und Medizinprodukte BfArM   (Germany)

Author keywords

Electrical remodeling; Myocardial hypertrophy; Structural remodelling

Indexed keywords

ALDOSTERONE; COLLAGEN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; POTASSIUM CHANNEL KV1.5; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART ATRIUM FIBRILLATION; HEART HYPERTROPHY; HEART MUSCLE POTENTIAL; HEART PACING; HEART WEIGHT; HISTOPATHOLOGY; MALE; MICROELECTRODE; NONHUMAN; OSMOTIC MINIPUMP; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINUS RHYTHM; TIBIA;

RATTUS;

EID: 84861394854     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000178483     Document Type: Article

References (42)

1. Shin H, Hashizume K, Iino Y, Koizumi K, Matayoshi T, Yozu R: Effects of atrial fibrillation on coronary artery bypass graft flow. Eur J Cardiothorac Surg 2003;23:175-178. (Pubitemid 36143778)
2. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE: Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a metaanalysis. J Am Coll Cardiol 2010;55:2299-2307.
3. Goette A: ANTIPAF: Angiotensin II-antagonist in paroxysmal atrial fibrillation trial. Eur Heart J 2010;31(S1).
4. Struthers AD: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995;16 Suppl N:103-106. (Pubitemid 26082329)
5. Sun Y, Ramires FJ, Weber KT: Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997;35:138-147. (Pubitemid 27374751)
6. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-1248. (Pubitemid 40523144)
7. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU: Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001;88:906-9, A8. (Pubitemid 32995932)
8. Dixen U, Ravn L, Soeby-Rasmussen C, Paulsen AW, Parner J, Frandsen E, Jensen GB: Raised plasma aldosterone and natriuretic peptides in atrial fibrillation. Cardiology 2007;108:35-39. (Pubitemid 47014348)
9. Tsai CT, Chiang FT, Tseng CD, Hwang JJ, Kuo KT, Wu CK, Yu CC, Wang YC, Lai LP, Lin JL: Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 2010;55:758-770.
10. Reil JC, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, Munz BM, Muller P, Steendijk P, Reil GH, Allessie MA, Bohm M, Neuberger HR: Aldosterone promotes atrial fibrillation. Eur Heart J 2011; in press.
11. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S: Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997;81:512-525. (Pubitemid 27432738)
12. Van Wagoner DR: Molecular basis of atrial fibrillation: a dream or a reality? J Cardiovasc Electrophysiol 2003;14:667-669. (Pubitemid 36724395)
13. Zhang H, Garratt CJ, Zhu J, Holden AV: Role of up-regulation of IK1 in action potential shortening associated with atrial fibrillation in humans. Cardiovasc Res 2005;66:493-502. (Pubitemid 40725761)
14. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kuhlkamp V: Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999;44:121-131. (Pubitemid 29431690)
15. + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 1997;80:772-781. (Pubitemid 27230051)
16. Brundel BJ, Van Gelder IC, Henning RH, Tieleman RG, Tuinenburg AE, Wietses M, Grandjean JG, van Gilst WH, Crijns HJ: Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 2001;103:684-690. (Pubitemid 32144197)
17. Sugiyama A, Takahara A, Honsho S, Nakamura Y, Hashimoto K: A simple in vivo atrial fibrillation model of rat induced by transesophageal atrial burst pacing. J Pharmacol Sci 2005;98:315-318. (Pubitemid 41296413)
18. Halbach M, Pillekamp F, Brockmeier K, Hescheler J, Muller-Ehmsen J, Reppel M: Ventricular slices of adult mouse heartsa new multicellular in vitro model for electrophysiological studies. Cell Physiol Biochem 2006;18:1-8.
19. Diedrichs H, Mei C, Frank KF, Boelck B, Schwinger RH: Calcineurin independent development of myocardial hypertrophy in transgenic rats overexpressing the mouse renin gene, TGR (mREN2) 27. J Mol Med 2004;82:688-695. (Pubitemid 39468493)
20. Moe GK, Rheinboldt WC, Abildskov JA: A computer model of atrial fibrillation. Am Heart J 1964;67:200-220.
21. Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ: Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988;62:395-410. (Pubitemid 18041961)
22. Lubitz SA, Ozcan C, Magnani JW, Kaab S, Benjamin EJ, Ellinor PT: Genetics of atrial fibrillation: implications for future research directions and personalized medicine. Circ Arrhythm Electrophysiol 2010;3:291-299.
23. Kharche S, Garratt CJ, Boyett MR, Inada S, Holden AV, Hancox JC, Zhang H: Atrial proarrhythmia due to increased inward rectifier current (I (K1)) arising from KCNJ2 mutation-a simulation study. Prog Biophys Mol Biol 2008;98:186-197.
24. Li J, McLerie M, Lopatin AN: Transgenic upregulation of IK1 in the mouse heart leads to multiple abnormalities of cardiac excitability. Am J Physiol Heart Circ Physiol 2004;287:H2790-H2802. (Pubitemid 39557153)
25. Xia M, Jin Q, Bendahhou S, He Y, Larroque MM, Chen Y, Zhou Q, Yang Y, Liu Y, Liu B, Zhu Q, Zhou Y, Lin J, Liang B, Li L, Dong X, Pan Z, Wang R, Wan H, Qiu W, Xu W, Eurlings P, Barhanin J, Chen Y: A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun 2005;332:1012-1019. (Pubitemid 40798187)
26. Gaborit N, Steenman M, Lamirault G, Le Meur N, Le Bouter S, Lande G, Leger J, Charpentier F, Christ T, Dobrev D, Escande D, Nattel S, Demolombe S: Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation 2005;112:471-481. (Pubitemid 41060786)
27. 2+ -ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: an insight into the mechanism of atrial electrical remodeling. J Am Coll Cardiol 1999;33:1231-1237.
28. Wettwer E, Hala O, Christ T, Heubach JF, Dobrev D, Knaut M, Varro A, Ravens U: Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 2004;110:2299-2306. (Pubitemid 39407330)
29. Brunner M, Kodirov SA, Mitchell GF, Buckett PD, Shibata K, Folco EJ, Baker L, Salama G, Chan DP, Zhou J, Koren G: In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. Am J Physiol Heart Circ Physiol 2003;285:H194-H203. (Pubitemid 36736430)
30. Tanabe Y, Hatada K, Naito N, Aizawa Y, Chinushi M, Nawa H, Aizawa Y: Overexpression of Kv1.5 in rat cardiomyocytes extremely shortens the duration of the action potential and causes rapid excitation. Biochem Biophys Res Commun 2006;345:1116-1121. (Pubitemid 43776519)
31. + channels in rat atrium: electrical remodeling in paroxysmal atrial tachycardia. Circulation 2000;101:2007-2014. (Pubitemid 30225284)
32. Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988;242:583-585. (Pubitemid 18263202)
33. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-1677. (Pubitemid 30307515)
34. Christ M, Meyer C, Sippel K, Wehling M: Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun 1995;213:123-129.
35. Mano A, Tatsumi T, Shiraishi J, Keira N, Nomura T, Takeda M, Nishikawa S, Yamanaka S, Matoba S, Kobara M, Tanaka H, Shirayama T, Takamatsu T, Nozawa Y, Matsubara H: Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation 2004;110:317-323. (Pubitemid 38955501)
36. Lister K, Autelitano DJ, Jenkins A, Hannan RD, Sheppard KE: Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1. Cardiovasc Res 2006;70:555-565.
37. Christ M, Gunther A, Heck M, Schmidt BM, Falkenstein E, Wehling M: Aldosterone, not estradiol, is the physiological agonist for rapid increases in cAMP in vascular smooth muscle cells. Circulation 1999;99:1485-1491. (Pubitemid 29140916)
38. Mori Y, Matsubara H, Folco E, Siegel A, Koren G: The transcription of a mammalian voltage-gated potassium channel is regulated by cAMP in a cell-specific manner. J Biol Chem 1993;268:26482-26493. (Pubitemid 23361727)
39. Boehmer C, Laufer J, Jeyaraj S, Klaus F, Lindner R, Lang F, Palmada M: Modulation of the voltage-gated potassium channel Kv1.5 by the SGK1 protein kinase involves inhibition of channel ubiquitination. Cell Physiol Biochem 2008;22:591-600.
40. Giovannardi S, Forlani G, Balestrini M, Bossi E, Tonini R, Sturani E, Peres A, Zippel R: Modulation of the inward rectifier potassium channel IRK1 by the Ras signaling pathway. J Biol Chem 2002;277:12158-12163. (Pubitemid 34952781)
41. Milliez P, Deangelis N, Rucker-Martin C, Leenhardt A, Vicaut E, Robidel E, Beaufils P, Delcayre C, Hatem SN: Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005;26:2193-2199. (Pubitemid 41408006)
42. Zhao J, Li J, Li W, Li Y, Shan H, Gong Y, Yang B: Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 2010;159:1584-1594.